v3.24.1.u1
Condensed Consolidated Balance Sheets - USD ($)
Mar. 31, 2024
Dec. 31, 2023
Current assets:    
Cash $ 3,414,263 $ 4,203,488
Advances on research and development contract services 78,016 78,016
Prepaid insurance 22,794 17,116
Other prepaid expenses 74,130 10,000
Total current assets 3,589,203 4,308,620
Total assets 3,589,203 4,308,620
Current liabilities:    
Accounts payable and accrued expenses, including $38,819 and $36,250 to related parties at March 31, 2024 and December 31, 2023, respectively 246,687 156,758
Research and development contract liabilities 216,149 157,100
Total current liabilities 462,836 313,858
Commitments and contingencies
Stockholders’ equity:    
Preferred Stock, $0.0001 par value; authorized – 10,000,000 shares; issued and outstanding – 350,000 shares of Series A Convertible Preferred Stock, $10.00 per share stated value, liquidation preference based on assumed conversion into common shares – 72,917 shares at March 31, 2024 and December 31, 2023 3,500,000 3,500,000
Common stock, $0.0001 par value; authorized – 100,000,000 shares; issued and outstanding – 2,249,290 shares at March 31, 2024 and December 31, 2023 225 225
Additional paid-in capital 49,079,192 48,976,265
Accumulated deficit (49,453,050) (48,481,728)
Total stockholders’ equity 3,126,367 3,994,762
Total liabilities and stockholders’ equity $ 3,589,203 $ 4,308,620

Source

HTML PDF
ZIP